New Panel Alert 🚨 Orion’s Immune Profiling Panel reveals 40 core biomarkers – spanning immune phenotype, immune function, and tissue architecture. Customize your panel by adding up to 10 more biomarkers for a total of up to 50 biomarkers, all completed in only 3 imaging rounds. Learn more ➡️ https://lnkd.in/eK5vySPn Contact us: https://lnkd.in/eqT2dNVD #SpatialBiology #SpatialProteomics #ImmuneProfiling
RareCyte, Inc.
Biotechnology Research
Seattle, Washington 5,439 followers
Unmatched Clarity in Spatial Biology & Liquid Biopsy
About us
We empower translational researchers and clinicians with advanced imaging platforms for spatial biology and liquid biopsy solutions. Our integrated platforms unlock deep biological insights from blood and tissue, helping biopharma and academia accelerate discovery and innovation. Visit our website to learn how we transform complex biology into actionable insights.
- Website
-
http://www.rarecyte.com
External link for RareCyte, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Seattle, Washington
- Type
- Privately Held
- Founded
- 2009
- Specialties
- Non-Invasive Prenatal Testing Research, Circulating Tumor Cell Research, Biomarkers, Rare Cell Analysis, Liquid Biopsy, Immuno-oncology, spatial biology, clinical trials, rare cell isolation, rare cell retrieval, tissue micro-region retrieval, IF microscopy, oncology, cell and gene therapy, tissue IF and H&E imaging, biomarkers, multiplex imaging, quantitative analysis, Spatial Imaging, Pathology, Spatial Proteomics, immunofluorescence, multiplex immunofluorescence, translational research, and Preclinical
Locations
-
Primary
2601 4th Ave
Seattle, Washington 98121, US
Employees at RareCyte, Inc.
Updates
-
We’re thrilled to be attending SC3 in Dallas! Looking to expand your core’s spatial biology platform offerings? Stop by our table to meet Xiaocong Chen and explore how the Orion platform can: ✅ Deliver high-throughput, 20-channel multiplex imaging ✅ Lower per-sample costs, expanding access to spatial biology ✅ Streamline studies with a familiar pathology workflow ✅ Simplify multiplex IF panel creation Let’s talk about how Orion can streamline your core’s spatial biology projects. Book a 1:1 meeting: https://lnkd.in/gaTqDygf #ABRF #SpatialBiology #Pathology #MultiplexIF ABRF - Association of Biomolecular Resource Facilities (ABRF)
-
-
Two views from our lab this morning! Want to have your research showcased in labs around the world? Submit your favorite images to our 2026 Calendar Image Contest. 📆 Winners will be featured in next year’s calendar and receive a canvas print of your image. Submissions close Oct 15. Enter here: https://lnkd.in/gcdJayPG 📸 Multiplex imaging of a human kidney biopsy exhibiting glomerular deposition disease. Jia-Yun Chen and Yilin Xu, Harvard Medical School #SpatialBiology #LiquidBiopsy #RareCyteCalendar
-
-
A beauty, indeed! High-plex immunofluorescence allows for unprecedented insights into tissue architecture and the molecular mechanisms. 🔎 You're looking at a high-grade colon adenocarcinoma hot tumor that contains prominent clusters of PD-L1 expression scattered throughout. #ColonCancer #SpatialBiology
Let's appreciate the beauty of applying a cell segmentation mask to a tissue map to analyze the tumor microenvironment. Multiplex immunofluorescence image taken on RareCyte, Inc.'s Orion™ and analyzed on Phenoplex™. Read the poster here: https://hubs.ly/Q03KZptV0
-
-
Tomorrow kicks off the “Mission possible – delivering translational impact” symposium in Helsinki! Make sure to stop by this presentation from local researcher, Ada Junquera Mencía, University of Helsinki. 🌟 “Single-cell spatial proteomics identifies cell-cycle–resolved tumor niches in chemotherapy-treated ovarian cancer” 📆 Thursday, Sept 25, 11:25 – 11:45 Symposium agenda: https://lnkd.in/dJmExeeX #SpatialProteomics #OvarianCancer #iCANSymposium
-
-
Excited for Biomarkers & Precision Medicine UK next week in London! Discover how spatial protein profiling is transforming translational research at our featured talk: "Spatial Biology at Scale with Orion Technology" Presented by: Mickael Meyrand 📆 Tuesday, Sept 30 at 3:50 PM 📍 Swing by RareCyte booth #62 Learn more: https://lnkd.in/gVbdiAYi Book a one-to-one meeting: https://lnkd.in/gJdWBgMY #BIOMUK2025 #SpatialBiology #Biomarkers
-
-
Heading to Helsinki this week? Join us at Mission possible – delivering translational impact, September 25-26. Don’t miss the keynote speaker, Dr. Peter Sorger from Harvard Medical School. 📌 Sept 25, 9:10–9:55 Keynote "Highly multiplexed spatial profiling for discovery and diagnosis" Want to discuss spatial protein profiling for your research? Set up a meeting with Alexandre Darmoise, PhD at the symposium: https://lnkd.in/dwkH49vH #iCANSymposium25 #SpatialBiology #TranslationalResearch
-
-
RareCyte, Inc. reposted this
Want to know how spatial biology can bridge discovery and translation? Don’t miss this Live Session with Zhihong (Z) Chen, CTO of OCCAM Immune, as he shares how to: - Design effective multiplex panels for clinical and translational research - Integrate RareCyte, Inc. Orion imaging with multi-omics datasets - Apply scalable approaches for large-cohort data analysis and interpretation Register now: https://lnkd.in/eEE7R9CH #SpatialBiology #TranslationalResearch #Biomarkers #MultiplexImaging #DigitalPathology #ImmunoOncology
-
Spatial biology is revealing powerful new biomarker candidates – but how do you translate discovery into clinical panels? 🎯 Join our live session with Dr. Zhihong (Z) Chen (OCCAM Immune, Icahn School of Medicine at Mount Sinai) for expert discussion, Q&A, and strategies for moving from high-plex exploration to clinically actionable panels. Register now to save your spot ➡️ https://lnkd.in/gp5jJ8Ht #SpatialBiology #SpatialProteomics #Biomarkers
-
-
💡 This study highlights how combining ctcDNA and cfDNA profiling deepens our understanding of metastatic prostate cancer. By analyzing blood samples from 35 patients at multiple time points using the HERCULES panel, it reveals the added value of assessing both circulating tumor cells and cfDNA. This dual approach may strengthen how clinicians monitor genetic changes and inform potential treatment choices for patients undergoing therapy. https://lnkd.in/ggqddSx8 Thank you to the authors! Daniel Bsteh, Amir Goldkorn and all others! #LiquidBiospy #ProstateCancer #CancerResearch #FridayRead